Cargando…

A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial

BACKGROUND: Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. METHODS: For this open-label, pragmatic, multicenter, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Anunnatsiri, Siriluck, Chaowagul, Wipada, Teparrukkul, Prapit, Chetchotisakd, Ploenchan, Tanwisaid, Kittisak, Khemla, Supphachoke, Narenpitak, Surapong, Pattarapongsin, Moragot, Kongsawasd, Wirod, Pisuttimarn, Pornrith, Thipmontree, Wilawan, Mootsikapun, Piroon, Chaisuksant, Seksan, Chierakul, Wirongrong, Day, Nicholas P J, Limmathurotsakul, Direk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662794/
https://www.ncbi.nlm.nih.gov/pubmed/32725199
http://dx.doi.org/10.1093/cid/ciaa1084
_version_ 1784613510468075520
author Anunnatsiri, Siriluck
Chaowagul, Wipada
Teparrukkul, Prapit
Chetchotisakd, Ploenchan
Tanwisaid, Kittisak
Khemla, Supphachoke
Narenpitak, Surapong
Pattarapongsin, Moragot
Kongsawasd, Wirod
Pisuttimarn, Pornrith
Thipmontree, Wilawan
Mootsikapun, Piroon
Chaisuksant, Seksan
Chierakul, Wirongrong
Day, Nicholas P J
Limmathurotsakul, Direk
author_facet Anunnatsiri, Siriluck
Chaowagul, Wipada
Teparrukkul, Prapit
Chetchotisakd, Ploenchan
Tanwisaid, Kittisak
Khemla, Supphachoke
Narenpitak, Surapong
Pattarapongsin, Moragot
Kongsawasd, Wirod
Pisuttimarn, Pornrith
Thipmontree, Wilawan
Mootsikapun, Piroon
Chaisuksant, Seksan
Chierakul, Wirongrong
Day, Nicholas P J
Limmathurotsakul, Direk
author_sort Anunnatsiri, Siriluck
collection PubMed
description BACKGROUND: Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. METHODS: For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis. We randomly assigned patients to stop treatment (12-week regimen) or continue treatment for another 8 weeks (20-week regimen). The primary end point was culture-confirmed recurrent melioidosis within 1 year after enrollment. The noninferiority margin was a hazard ratio (HR) of 2.0. The secondary composite end point, combining overall recurrent melioidosis and mortality, was assessed post hoc. RESULTS: We enrolled 658 patients: 322 to the 12-week regimen and 336 to the 20-week regimen. There were 5 patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen who developed culture-confirmed recurrent melioidosis (HR, 2.66; 95% confidence interval [CI], .52–13.69). The criterion for noninferiority of the primary event was not met (1-sided P = .37). However, all-cause mortality was significantly lower in the 12-week regimen group than in the 20-week regimen group (1 [.3%] vs 11 [3%], respectively; HR, 0.10; 95% CI, .01–.74). The criterion for noninferiority of the secondary composite end point, combining overall recurrent melioidosis and mortality, was met (1-sided P = .022). CONCLUSIONS: Based on the lower total mortality and noninferiority of the secondary composite end point observed, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis. CLINICAL TRIALS REGISTRATION: NCT01420341.
format Online
Article
Text
id pubmed-8662794
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86627942021-12-13 A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial Anunnatsiri, Siriluck Chaowagul, Wipada Teparrukkul, Prapit Chetchotisakd, Ploenchan Tanwisaid, Kittisak Khemla, Supphachoke Narenpitak, Surapong Pattarapongsin, Moragot Kongsawasd, Wirod Pisuttimarn, Pornrith Thipmontree, Wilawan Mootsikapun, Piroon Chaisuksant, Seksan Chierakul, Wirongrong Day, Nicholas P J Limmathurotsakul, Direk Clin Infect Dis Online Only Articles BACKGROUND: Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. METHODS: For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis. We randomly assigned patients to stop treatment (12-week regimen) or continue treatment for another 8 weeks (20-week regimen). The primary end point was culture-confirmed recurrent melioidosis within 1 year after enrollment. The noninferiority margin was a hazard ratio (HR) of 2.0. The secondary composite end point, combining overall recurrent melioidosis and mortality, was assessed post hoc. RESULTS: We enrolled 658 patients: 322 to the 12-week regimen and 336 to the 20-week regimen. There were 5 patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen who developed culture-confirmed recurrent melioidosis (HR, 2.66; 95% confidence interval [CI], .52–13.69). The criterion for noninferiority of the primary event was not met (1-sided P = .37). However, all-cause mortality was significantly lower in the 12-week regimen group than in the 20-week regimen group (1 [.3%] vs 11 [3%], respectively; HR, 0.10; 95% CI, .01–.74). The criterion for noninferiority of the secondary composite end point, combining overall recurrent melioidosis and mortality, was met (1-sided P = .022). CONCLUSIONS: Based on the lower total mortality and noninferiority of the secondary composite end point observed, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis. CLINICAL TRIALS REGISTRATION: NCT01420341. Oxford University Press 2020-07-29 /pmc/articles/PMC8662794/ /pubmed/32725199 http://dx.doi.org/10.1093/cid/ciaa1084 Text en © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Online Only Articles
Anunnatsiri, Siriluck
Chaowagul, Wipada
Teparrukkul, Prapit
Chetchotisakd, Ploenchan
Tanwisaid, Kittisak
Khemla, Supphachoke
Narenpitak, Surapong
Pattarapongsin, Moragot
Kongsawasd, Wirod
Pisuttimarn, Pornrith
Thipmontree, Wilawan
Mootsikapun, Piroon
Chaisuksant, Seksan
Chierakul, Wirongrong
Day, Nicholas P J
Limmathurotsakul, Direk
A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
title A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
title_full A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
title_fullStr A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
title_full_unstemmed A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
title_short A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
title_sort comparison between 12 versus 20 weeks of trimethoprim-sulfamethoxazole as oral eradication treatment for melioidosis: an open-label, pragmatic, multicenter, non-inferiority, randomized controlled trial
topic Online Only Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662794/
https://www.ncbi.nlm.nih.gov/pubmed/32725199
http://dx.doi.org/10.1093/cid/ciaa1084
work_keys_str_mv AT anunnatsirisiriluck acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chaowagulwipada acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT teparrukkulprapit acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chetchotisakdploenchan acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT tanwisaidkittisak acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT khemlasupphachoke acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT narenpitaksurapong acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT pattarapongsinmoragot acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT kongsawasdwirod acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT pisuttimarnpornrith acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT thipmontreewilawan acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT mootsikapunpiroon acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chaisuksantseksan acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chierakulwirongrong acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT daynicholaspj acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT limmathurotsakuldirek acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT anunnatsirisiriluck comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chaowagulwipada comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT teparrukkulprapit comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chetchotisakdploenchan comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT tanwisaidkittisak comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT khemlasupphachoke comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT narenpitaksurapong comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT pattarapongsinmoragot comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT kongsawasdwirod comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT pisuttimarnpornrith comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT thipmontreewilawan comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT mootsikapunpiroon comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chaisuksantseksan comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT chierakulwirongrong comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT daynicholaspj comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial
AT limmathurotsakuldirek comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial